<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2000
-------------
or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
Commission File Number: 0-22669
----------------------
AURORA BIOSCIENCES CORPORATION
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 33-0669859
--------------------------------------------------------------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
11010 Torreyana Road, San Diego, CA 92121
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip code)
(858) 404-6600
--------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
--------------------------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports
requiredto be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
Outstanding at
Class July 31, 2000
----- -------------
Common Stock, $.001 par value 20,204,753
<PAGE> 2
AURORA BIOSCIENCES CORPORATION
FORM 10-Q
INDEX
<TABLE>
<CAPTION>
PAGE NO.
--------
<S> <C>
PART I. FINANCIAL INFORMATION
ITEM 1. Financial Statements
Balance Sheets - June 30, 2000 (Unaudited) and December 31, 1999............................3
Statements of Operations (Unaudited) - Three and six months ended June 30, 2000 and 1999....4
Statements of Cash Flows (Unaudited) - Three and six months ended June 30,
2000 and 1999............................................................................5
Notes to Financial Statements (Unaudited)...................................................6
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of
Operations...............................................................................8
PART II. OTHER INFORMATION
ITEM 4. Submission of Matters to a Vote of Security Holders...............................11
ITEM 5. Other Information.................................................................11
ITEM 6. Exhibits and Reports on Form 8-K..................................................12
SIGNATURE......................................................................................13
</TABLE>
2
<PAGE> 3
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS.
AURORA BIOSCIENCES CORPORATION
BALANCE SHEETS
<TABLE>
<CAPTION>
June 30, December 31,
2000 1999
------------- -------------
(Unaudited)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 24,735,010 $ 15,934,352
Investment securities, available-for-sale 82,962,614 20,683,696
Accounts receivable 15,577,355 5,282,485
Notes receivable from officers and employees 50,000 50,000
Prepaid expenses 1,475,316 1,443,840
Other current assets 4,087,416 1,623,301
------------- -------------
Total current assets 128,887,711 45,017,674
Equipment, furniture and leaseholds, net 11,714,264 11,892,398
Notes receivable from officers and employees 227,000 115,000
Other assets 10,052,408 6,837,388
------------- -------------
Total assets $ 150,881,383 $ 63,862,460
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 4,960,357 $ 3,832,428
Accrued compensation 2,619,391 2,219,172
Other current liabilities 1,194,900 442,200
Unearned revenue 13,324,171 10,214,848
Capital lease and loan obligations, current portion 2,526,244 2,497,046
------------- -------------
Total current liabilities 24,625,063 19,205,694
Capital lease and loan obligations, less current portion 4,587,854 4,342,726
Stockholders' equity:
Preferred stock, $.001 par value; 7,500,000 shares
authorized and no shares issued and outstanding -- --
Common stock, $.001 par value, 50,000,000 shares
authorized, 20,173,684 and 17,442,741 shares issued and
outstanding at June 30, 2000 and December 31, 1999, 20,173 17,443
respectively
Additional paid-in capital 138,336,117 62,754,348
Accumulated other comprehensive income (loss) 1,096,334 (48,567)
Deferred compensation (464,845) (830,112)
Accumulated deficit (17,319,313) (21,579,072)
------------- -------------
Total stockholders' equity 121,668,466 40,314,040
------------- -------------
Total liabilities and stockholders' equity $ 150,881,383 $ 63,862,460
============= =============
</TABLE>
See accompanying notes.
3
<PAGE> 4
AURORA BIOSCIENCES CORPORATION
STATEMENTS OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
Three Months Ended June 30, Six Months Ended June 30,
--------------------------------- ---------------------------------
2000 1999 2000 1999
------------ ------------ ------------ ------------
<S> <C> <C> <C> <C>
Revenue $ 17,529,110 $ 13,041,714 $ 30,329,350 $ 19,560,778
Operating expenses:
Cost of revenue 9,171,839 7,240,471 16,975,456 13,167,139
Research and development 3,393,447 3,213,468 6,012,428 6,064,413
Selling, general and administrative 3,834,836 3,191,187 7,102,180 5,565,378
------------ ------------ ------------ ------------
Total operating expenses 16,400,122 13,645,126 30,090,064 24,796,930
------------ ------------ ------------ ------------
Income (loss) from operations 1,128,988 (603,412) 239,286 (5,236,152)
Interest and other income 3,512,865 338,952 4,611,936 722,518
Interest expense (169,986) (169,030) (351,463) (343,609)
------------ ------------ ------------ ------------
Income (loss) before taxes 4,471,867 (433,490) 4,499,759 (4,857,243)
Income taxes (240,000) -- (240,000) --
------------ ------------ ------------ ------------
Net income (loss) $ 4,231,867 $ (433,490) $ 4,259,759 $ (4,857,243)
============ ============ ============ ============
Basic net income (loss) per share $ 0.21 $ (0.03) $ 0.22 $ (0.29)
============ ============ ============ ============
Diluted net income (loss) per share $ 0.19 $ (0.03) $ 0.20 $ (0.29)
============ ============ ============ ============
Shares used in computing:
Basic income (loss) per share 19,958,914 16,897,201 19,293,171 16,816,924
============ ============ ============ ============
Diluted income (loss) per share 22,227,349 16,897,201 21,768,824 16,816,924
============ ============ ============ ============
</TABLE>
See accompanying notes.
4
<PAGE> 5
AURORA BIOSCIENCES CORPORATION
STATEMENTS OF CASH FLOWS
(UNAUDITED)
<TABLE>
<CAPTION>
Six Months Ended June 30,
---------------------------------
2000 1999
------------ ------------
<S> <C> <C>
OPERATING ACTIVITIES:
Net income (loss) $ 4,259,759 $ (4,857,243)
Adjustments to reconcile net income (loss)
to net cash used in operating activities:
Depreciation and amortization 1,710,989 1,579,669
Amortization of deferred compensation 336,662 475,075
Gain from sale of investment (1,729,736) --
Other non-cash items, net 158,708 --
Changes in operating assets and liabilities:
Accounts receivable (10,294,870) (3,943,169)
Prepaid expenses and other current assets (2,495,591) (1,713,950)
Other assets (167,173) (605,311)
Accounts payable and accrued compensation 1,528,148 2,627,146
Other current liabilities 752,700 247,916
Unearned revenue 3,109,323 4,590,167
------------ ------------
Net cash used in operating activities (2,831,081) (1,599,700)
INVESTING ACTIVITIES:
Purchases of short-term investments (76,946,482) (2,065,645)
Sales and maturities of short-term investments 14,457,877 5,786,855
Purchases of property and equipment (941,903) (347,013)
Notes receivable from officers and employees (132,000) 250,000
Other assets 36,477 347,971
------------ ------------
Net cash provided by (used in) investing activities (63,526,031) 3,972,168
FINANCING ACTIVITIES:
Private placement of common stock, net 70,940,179 --
Other issuances of common stock, net 4,534,217 539,495
Proceeds from capital lease and loan obligations 1,129,887 --
Principal payments on capital lease and loan obligations (1,446,513) (1,025,110)
------------ ------------
Net cash provided by (used in) financing activities 75,157,770 (485,615)
------------ ------------
Net increase in cash and cash equivalents 8,800,658 1,886,853
Cash and cash equivalents at beginning of period 15,934,352 9,477,916
------------ ------------
Cash and cash equivalents at end of period $ 24,735,010 $ 11,364,769
============ ============
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid $ 351,463 $ 343,609
============ ============
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND
FINANCING ACTIVITIES:
Property and equipment acquired under capital leases
and loans $ 590,952 $ 897,498
============ ============
</TABLE>
See accompanying notes.
5
<PAGE> 6
AURORA BIOSCIENCES CORPORATION
JUNE 30, 2000
1. BASIS OF PRESENTATION
The accompanying unaudited financial statements of Aurora Biosciences
Corporation ("Aurora" or the "Company") have been prepared in accordance
with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, they do not include all of the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all adjustments,
consisting of normal recurring adjustments, considered necessary for a fair
presentation have been included. Interim results are not necessarily
indicative of results for a full year.
The balance sheet at December 31, 1999 has been derived from the audited
financial statements at that date but does not include all of the
information and footnotes required by generally accepted accounting
principles for complete financial statements.
These financial statements should be read in conjunction with the audited
financial statements and footnotes thereto included in the Company's Annual
Report on Form 10-K for the year ended December 31, 1999, as filed with the
Securities and Exchange Commission ("SEC").
2. ACCOUNTS RECEIVABLE
Included in accounts receivable are unbilled amounts totaling $10,151,266
and $3,465,264 at June 30, 2000 and December 31, 1999, respectively.
Unbilled receivables are not billable in accordance with contract terms
until some future date. The unbilled receivables at June 30, 2000 are
expected to be billed and collected within one year.
3. GAIN FROM SALE OF INVESTMENT
Interest and other income includes a $1.7 million gain from the sale of
shares of Cytovia, Inc. upon its acquisition by Maxim Pharmaceuticals, Inc.
in June 2000.
6
<PAGE> 7
AURORA BIOSCIENCES CORPORATION
JUNE 30, 2000
4. INCOME (LOSS) PER SHARE
The following table sets forth the computation of basic and diluted net
income (loss) per share for the three and six months periods ended June 30,
2000 and 1999:
<TABLE>
<CAPTION>
Three Months Ended June 30, Six Months Ended June 30,
-------------------------------- --------------------------------
2000 1999 2000 1999
------------ ------------ ------------ ------------
<S> <C> <C> <C> <C>
Numerator:
Net income (loss) $ 4,231,867 $ (433,490) $ 4,259,759 $ (4,857,243)
============ ============ ============ ============
Denominator:
Shares used in basic income
(loss) per share computations -
weighted average common shares
outstanding 19,958,914 16,897,201 19,293,171 16,816,924
Effect of dilutive securities:
Nonvested common stock 34,577 -- 49,678 --
Common stock options 2,233,858 -- 2,425,975 --
------------ ------------ ------------ ------------
Dilutive securities subtotal 2,268,435 -- 2,475,653 --
------------ ------------ ------------ ------------
Shares used in diluted income
(loss) per share computations 22,227,349 16,897,201 21,768,824 16,816,924
============ ============ ============ ============
Basic net income (loss) per share $ 0.21 $ (0.03) $ 0.22 $ (0.29)
============ ============ ============ ============
Diluted net income (loss) per share $ 0.19 $ (0.03) $ 0.20 $ (0.29)
============ ============ ============ ============
</TABLE>
5. COMPREHENSIVE INCOME (LOSS)
Total comprehensive income (loss) was $5,541,724 and ($481,670) for the
three months ended June 30, 2000 and 1999, respectively and $5,404,660 and
($4,869,046) for the six months ended June 30, 2000 and 1999, respectively.
Total comprehensive income (loss) for the three and six months ended June
30, 2000 includes unrealized gains from investments totaling $1,309,857 and
$1,144,901, respectively.
6. COLLABORATIVE AGREEMENTS
In May 2000, the Company entered into a five-year collaboration with the
Cystic Fibrosis Foundation for assay development and screening services
which focuses on a treatment for cystic fibrosis. Committed funding
payments and project progress payments to Aurora could total approximately
$30 million over the course of the collaboration, before clinical milestone
payments.
7
<PAGE> 8
AURORA BIOSCIENCES CORPORATION
JUNE 30, 2000
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
This Form 10-Q contains certain statements of a forward-looking nature relating
to future events or our future financial performance. Such statements are only
predictions and actual events or results may differ materially. Factors that
could cause or contribute to such differences include, without limitation, those
discussed in this Item 2 as well as those discussed in our Annual Report on Form
10-K for the year ended December 31, 1999 and Form 10-Q for the quarter ended
March 31, 2000, as filed with the Securities and Exchange Commission.
OVERVIEW
Aurora Biosciences Corporation designs, develops and commercializes advanced
drug discovery technologies, services and systems to accelerate and enhance the
discovery of new medicines. Our core technologies include a broad portfolio of
proprietary fluorescent assay technologies, including our GeneBLAzer(TM) and
VIPR(TM) technologies; our functional genomics GenomeScreen(TM) program; our
automated master compound store, the AMCS; our ultra-high throughput screening
system, the UHTSS Platform; and subsystems to miniaturize and automate drug
screening and profiling assays.
We had an accumulated deficit of $17.3 million as of June 30, 2000. Our
objective for 2000 is to maintain profitability for the full year. Our ability
to maintain profitability will depend in part on our ability to successfully
complete development, manufacture and delivery of UHTSS Platforms and other
systems that meet contractual specifications, continue to provide drug discovery
services to pharmaceutical and biotechnology customers and achieve further
growth in sales of our technologies, services and systems.
Revenue is predominately derived from sales of services, technology, instruments
and intellectual property licenses. Revenue to date has been generated from a
limited number of customers in the life sciences industry in the U.S. and
Europe. Many of our agreements provide for future milestone payments from drug
development achievements and royalties from the sale of products derived from
certain of our technologies. However, customers may not ever generate products
from technology provided by us and thus we may not ever receive milestone
payments or royalties. We believe our ability to maintain profitability is not
dependent on receipt of milestone payments or royalties.
We may encounter significant fluctuations in our quarterly financial performance
depending on factors such as revenue from existing and future contracts and
collaborations, timing of the delivery of technologies and systems and the
completion of contracted service commitments to our customers. We will also
continue to invest in new technologies to expand our core drug discovery
capabilities. Accordingly, our results of operations for any period may not be
comparable to, or predictive of, the results of operations for any other period.
RESULTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2000 AND 1999
Total revenue increased 34% from the three months ended June 30, 1999 to the
three months ended June 30, 2000 (the "three-month period") and increased 55%
from the six months ended June 30, 1999 to the six months ended June 30, 2000
(the "six-month period"). The increases in revenue resulted from our existing
collaborations with Pfizer (including our original collaboration with
Warner-Lambert, acquired by Pfizer in June 2000) and new agreements entered into
since June 30, 1999, including ion channel technology agreements with Glaxo
Wellcome, American Home Products and R.W. Johnson Pharmaceutical Research
Institute.
8
<PAGE> 9
AURORA BIOSCIENCES CORPORATION
JUNE 30, 2000
Total operating expenses increased 20% for the three-month period and 21% for
the six-month period. The increases in operating expenses resulted primarily
from our growth, reflected by the increase to 214 full-time employees at June
30, 2000 from 169 full-time employees at June 30, 1999. Cost of revenue
increased 27% and 29% for the three-month and six-month periods, respectively,
related to the continuing development of the UHTSS Platform, the AMCS system and
screening subsystems for our customers, as well as instrument sales and drug
discovery services performed under the new agreements. Research and development
expenses increased 6% for the three-month period and were constant for the
six-month period, despite our overall growth, with the assignment of scientific
resources to support revenue-generating programs. Selling, general and
administrative expenses increased 20% and 28% for the three-month and six-month
periods, respectively, primarily attributable to the growth of the sales,
marketing and legal functions in addition to increased professional services
expenses.
Net interest and other income increased 625% and 365% for the three-month and
six-month periods, respectively, due to the increased cash and investment
balances resulting from a $71 million private placement of 1.8 million shares of
common stock in February 2000 and a $1.7 million gain from the sale of shares of
Cytovia, Inc. upon its acquisition by Maxim Pharmaceuticals, Inc. in June 2000.
LIQUIDITY AND CAPITAL RESOURCES
At June 30, 2000, we held cash, cash equivalents and investment securities
available-for-sale of $108 million and working capital of $104 million. We have
funded our operations since inception primarily through the issuance of equity
securities with aggregate net proceeds of $134 million, receipts from corporate
collaborations and strategic technology alliances of $121 million, capital
equipment lease and loan financing of $13 million and interest income of $9
million.
We have entered into certain contractual commitments, subject to satisfactory
performance by third parties, which obligate expenditures totaling approximately
$6.0 million over the next four years.
Our strategy for the UHTSS Platform includes the establishment of a syndicate of
collaborators to provide us with funding for development, technology and
personnel resources and payments for system validation. The UHTSS Platform
co-development syndicate currently includes Bristol-Myers, Warner-Lambert
(acquired by Pfizer in June 2000), Merck and Pfizer. We have also entered into
agreements with Warner-Lambert and Pfizer to develop AMCS systems. In addition,
we have entered into collaborations with Cystic Fibrosis Foundation and Families
of Spinal Muscular Atrophy to provide screen development and/or screening
services, and with Warner-Lambert, Merck, Becton Dickinson, the National Cancer
Institute and Pfizer for functional genomics programs. We have entered into ion
channel technology agreements with Bristol-Myers, Eli Lilly and Company, Glaxo
Wellcome, American Home Products, Merck, N.V. Organon and R.W. Johnson
Pharmaceutical Research Institute. Other collaborations include a combinatorial
chemistry agreement with SIDDCO to synthesize large libraries of chemical
compounds for us.
Our ability to achieve sustained profitability will be dependent upon our
ability to deliver and obtain acceptance of equipment by collaborators, perform
contracted screening services, sell or license new products and services, and to
increase market share of existing discovery services and technologies by
agreements with new collaborators and expansion of agreements with existing
collaborators. We may not be able to meet our revenue goals or sustain
profitability on a quarterly or annual basis. Although we are actively seeking
to enter into additional collaborations, we may not be able to negotiate
additional collaborative agreements on acceptable terms, if at all. Some of our
current collaborative agreements may
9
<PAGE> 10
AURORA BIOSCIENCES CORPORATION
JUNE 30, 2000
be terminated by the collaborator without cause upon short notice, which would
result in loss of anticipated revenue. Although certain of our collaborators
would be required to pay some penalties in the event they terminate their
agreements without cause, any of our collaborators may elect to terminate their
agreements with us. In addition, collaborators may terminate their agreements
for cause if we cannot deliver the technology in accordance with the agreements.
Our collaborators may not perform their obligations as expected and we may not
derive any additional revenue from the agreements. Current or future
collaborative agreements may not be successful and provide us with expected
benefits. Termination of our existing or future collaborative agreements, or the
failure to enter into a sufficient number of additional collaborative agreements
on favorable terms or generate sufficient revenues from our services and
technologies could have a material adverse effect on our business, financial
condition or results of operations.
The complexity of both the UHTSS Platform and AMCS has led to unexpected delays
in developing these platforms that may lead to financial penalties and
contractual disputes regarding the delivery and acceptance of these platforms by
our customers. Because we are also dependent in part on the performance of our
customers and suppliers in order to deliver these platforms, our ability to
timely deliver these platforms may be outside of our control. Some of our
agreements with our customers provide for penalties to be paid by us if we do
not meet development schedules contained in the agreements. Our agreement with
Bristol-Myers provides for penalty payments up to a maximum of $1,000,000 if we
fail to deliver the completed UHTSS Platform by a specified time. Our agreement
with Warner-Lambert provides for penalty payments up to a maximum of $888,300 if
we fail to deliver the completed AMCS according to a specified development
schedule. If we fail to meet the development schedules under our agreements with
Bristol-Myers and Warner-Lambert, the payment of penalties could have a material
adverse effect on our business, financial condition or results of operations.
We may be required to raise additional capital over the next several years in
order to expand our operations or acquire new technology. This capital may be
raised through additional public or private equity financings, borrowings and
other available sources. Our business or operations may change in a manner that
would consume available resources more rapidly than anticipated and substantial
additional funding may be required before we can sustain profitable operations.
We may not continue to generate sales from and receive payments under existing
collaborative agreements and existing or potential revenue may not be adequate
to fund our operations. If additional funding becomes necessary, it may not be
available on favorable terms, if at all. If adequate funds are not available, we
may be required to curtail operations significantly or to obtain funds by
entering into arrangements with others that may have a material adverse effect
on our business, financial condition or results of operations.
10
<PAGE> 11
AURORA BIOSCIENCES CORPORATION
JUNE 30, 2000
PART II - OTHER INFORMATION
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
Our Annual Meeting of Stockholders was held on May 23, 2000. The following
actions were taken at the Annual Meeting:
(a) The following Directors were elected for a one-year term expiring at the
2001 annual meeting:
<TABLE>
<CAPTION>
Name Shares Voted For Shares Withheld
---- ---------------- ---------------
<S> <C> <C>
Stuart J.M. Collinson, Ph.D. 14,944,354 48,760
James C. Blair, Ph.D. 14,951,772 41,342
Hugh Y. Rienhoff, Jr., M.D. 14,957,149 35,965
Roy A. Whitfield 14,958,544 34,570
Timothy J. Wollaeger 14,962,170 30,944
</TABLE>
(b) A proposal to amend our 1996 Stock Plan to increase the aggregate number of
shares of Common Stock authorized for issuance under such plan by 2,000,000
shares was approved.
<TABLE>
<S> <C>
Shares Voted For 7,777,611
Shares Voted Against 2,754,981
Shares Abstain 444,872
</TABLE>
(c) A proposal to amend our Non-Employee Directors' Stock Option Plan to
increase the number of options to purchase shares of our common stock to be
granted to non-employee directors upon first joining the Board from 16,000
to 20,000 and to increase the number of options to purchase shares of our
common stock to be granted annually to non-employee directors serving on
the Board from 4,000 to 5,000 was approved. It was also approved that the
Director's Plan provide for vesting of new options granted annually to
non-employee directors over a period of one year.
<TABLE>
<S> <C>
Shares Voted For 12,033,839
Shares Voted Against 2,511,061
Shares Abstain 448,214
</TABLE>
(d) The selection of Ernst & Young LLP as independent auditors for the Company
for the fiscal year ending December 31, 2000 was ratified.
<TABLE>
<S> <C>
Shares Voted For 14,963,968
Shares Voted Against 14,884
Shares Withheld 14,262
</TABLE>
ITEM 5. OTHER INFORMATION
Pursuant to our bylaws, stockholders who wish to bring matters or propose
nominees for director at our 2001 annual meeting of stockholders must provide
specified information to us no later than December 20, 2000 (unless such matters
are included in our proxy statement pursuant to Rule 14a-8 under the Securities
Exchange Act of 1934, as amended).
11
<PAGE> 12
AURORA BIOSCIENCES CORPORATION
JUNE 30, 2000
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits:
<TABLE>
<S> <C>
10.58* Cystic Fibrosis Research Alliance and Commercialization
Agreement effective as of May 19, 2000 between the Registrant
and the Cystic Fibrosis Foundation.
27.1 Financial Data Schedule related to the Financial Statements for
the period ended June 30, 2000.
</TABLE>
----------
* The Company has requested confidential treatment with respect to
certain portions of this exhibit. Omitted portions have been
filed separately with the Securities and Exchange Commission.
(b) Reports on Form 8-K:
No reports on Form 8-K were filed during the quarter ended June 30,
2000.
12
<PAGE> 13
AURORA BIOSCIENCES CORPORATION
June 30, 2000
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed in its behalf by the
undersigned thereunto duly authorized.
Aurora Biosciences Corporation
Date: August 11, 2000 By: /s/ John Pashkowsky
-------------------------------------
John Pashkowsky
Vice President, Finance and Treasurer
(on behalf of the Registrant and as
Registrant's Principal Financial and
Accounting Officer)
